Alexandria Venture Investments returned for a series B round that increased the precision oncology drug developer's overall funding to over $150m.
US-based cancer therapy developer Boundless Bio completed a $105m series B round that included Alexandria Venture Investments, the venture capital arm of life sciences real estate investment trust Alexandria Real Estate Equities. Investment management firm RA Capital Management and VC firm Nextech Invest co-led round, which also featured investment and financial services group Fidelity Management…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.